Children's Hospital Westmead Clinical School, The University of Sydney, Sydney, New South Wales, Australia.
NHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Obes Rev. 2023 Jun;24(6):e13561. doi: 10.1111/obr.13561. Epub 2023 Mar 15.
This systematic review examined change in eating disorder risk during weight management interventions. Four databases and clinical trials registries were searched in March and May 2022, respectively, to identify behavioral weight management intervention trials in adults with overweight/obesity measuring eating disorder symptoms at pre- and post-intervention or follow-up. Random effects meta-analyses were conducted examining within group change in risk. Of 12,023 screened, 49 were eligible (n = 6337, mean age range 22.1 to 59.9 years, mean (SD) 81(20.4)% female). Interventions ranged from 4 weeks to 18 months, with follow-up of 10 weeks to 36 months post-intervention. There was a within group reduction in global eating disorder scores (20 intervention arms; Hedges' g = -0.27; 95% CI -0.36, -0.17; I 67.1%) and binge eating (49 intervention arms; -0.66; 95% CI -0.76, -0.56; I 82.7%) post-intervention, both maintained at follow-up. Of 14 studies reporting prevalence or episodes of binge eating, all reported a reduction. Four studies reported eating disorder symptoms, not present at baseline, in a subset of participants (0%-6.5%). Overall, behavioral weight management interventions do not increase eating disorder symptoms for most adults; indeed, a modest reduction is seen post-intervention and follow-up. A small subset of participants may experience disordered eating; therefore, monitoring for the emergence of symptoms is important.
本系统评价考察了体重管理干预过程中进食障碍风险的变化。分别于 2022 年 3 月和 5 月检索了四个数据库和临床试验注册处,以确定针对超重/肥胖成年人的行为体重管理干预试验,这些试验在干预前和干预后或随访时测量进食障碍症状。采用随机效应荟萃分析来观察组内风险变化。在 12023 篇筛选文章中,有 49 篇符合条件(n=6337 人,平均年龄范围 22.1 至 59.9 岁,平均(SD)81(20.4)%为女性)。干预措施的持续时间从 4 周到 18 个月不等,随访时间从干预后 10 周到 36 个月不等。在干预后和随访时,整体进食障碍评分(20 个干预组;Hedges'g=-0.27;95%置信区间-0.36,-0.17;I 67.1%)和暴饮暴食(49 个干预组;-0.66;95%置信区间-0.76,-0.56;I 82.7%)均呈组内下降,且在随访时保持不变。在 14 项报告暴食症患病率或发作的研究中,所有研究均报告有所减少。四项研究报告在亚组参与者(0%-6.5%)中存在基线时不存在的进食障碍症状。总的来说,大多数成年人进行行为体重管理干预后不会增加进食障碍症状;实际上,干预后和随访时会出现轻微减少。一小部分参与者可能会出现饮食失调;因此,监测症状的出现很重要。